The European Medicines Agency (EMA) has signed a four-year agreement with Adis, a global provider of drug information, for AdisInsight, a database for drug research and development, disease treatment and decision making. Adis is part of scientific, technical and medical publisher Springer.
Based on trusted, scientifically sound data, AdisInsight brings together essential information on drugs in commercial development, key clinical trials, deals undertaken and safety profiles in one database. It is available for preview at adisinsight.springer.com.
EMA announced earlier this year that they were seeking a comprehensive drug database to provide scientific, economic and industry-related information. Although EMA had been using the old Adis databases for two years, the publisher was required to submit a new tender as part of the Agency's procurement process. Database users within the Agency will now begin integrating the new AdisInsight platform into their workflows with support from the AdisInsight product experts who will be on hand to deliver training and guidance.
The European Medicines Agency (EMA) is a decentralised agency of the European Union, located in London. The EMA's main responsibility is the protection and promotion of public and animal health through the evaluation and supervision of medicines for human and veterinary use.
Brought to you by Scope e-Knowledge Center, a world-leading provider of abstraction, indexing, entity extraction and knowledge organisation models (Taxonomies, Thesauri and Ontologies).
